Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Consolidated Net Income (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Consolidated Net Income for 8 consecutive years, with -$87.2 million as the latest value for Q1 2026.

  • Quarterly Consolidated Net Income fell 54.7% to -$87.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$295.3 million through Feb 2026, down 41.69% year-over-year, with the annual reading at -$264.5 million for FY2025, 36.62% down from the prior year.
  • Consolidated Net Income for Q1 2026 was -$87.2 million at Nurix Therapeutics, down from -$78.2 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$24.3 million in Q2 2023, with the low at -$87.2 million in Q1 2026.
  • Average Consolidated Net Income over 5 years is -$51.1 million, with a median of -$45.4 million recorded in 2022.
  • The sharpest move saw Consolidated Net Income soared 46.53% in 2023, then tumbled 83.49% in 2024.
  • Over 5 years, Consolidated Net Income stood at -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then plummeted by 39.55% to -$58.5 million in 2024, then tumbled by 33.6% to -$78.2 million in 2025, then decreased by 11.45% to -$87.2 million in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$87.2 million, -$78.2 million, and -$86.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.